Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma

FATE : 31.68 (-2.31%)
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

FATE : 31.68 (-2.31%)
Fate Therapeutics: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $33.5 million in its first quarter.

FATE : 31.68 (-2.31%)
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress

Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates

FATE : 31.68 (-2.31%)
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?

Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FATE : 31.68 (-2.31%)
What's in the Cards for Maxar (MAXR) This Earnings Season?

Lower revenues in the Space Infrastructure segment are likely to get reflected on Maxar's (MAXR) first-quarter 2020 results.

LOGI : 59.31 (-0.22%)
FATE : 31.68 (-2.31%)
GO : 36.03 (-2.12%)
MAXR : 16.41 (+8.89%)
Fate Therapeutics Announces Changes to its Board of Directors

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the...

FATE : 31.68 (-2.31%)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 31.68 (-2.31%)
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)

Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FATE : 31.68 (-2.31%)
Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting

Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB

FATE : 31.68 (-2.31%)
Fate Therapeutics (FATE) is a Great Momentum Stock: Should You Buy?

Does Fate Therapeutics (FATE) have what it takes to be a top stock pick for momentum investors? Let's find out.

FATE : 31.68 (-2.31%)
Is Fate Therapeutics (FATE) Stock Outpacing Its Medical Peers This Year?

Is (FATE) Outperforming Other Medical Stocks This Year?

FATE : 31.68 (-2.31%)
Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

PRGO : 55.44 (+1.22%)
FATE : 31.68 (-2.31%)
PETQ : 30.24 (-1.43%)
ALLO : 48.94 (+1.62%)
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

GILD : 75.16 (-3.43%)
INCY : 101.75 (-0.16%)
IMMU : 33.42 (-0.51%)
ALNY : 133.57 (-1.26%)
AMGN : 226.91 (-1.21%)
FATE : 31.68 (-2.31%)
VIR : 35.35 (+3.42%)
Is Fate Therapeutics (FATE) Stock a Solid Choice Right Now?

Fate Therapeutics (FATE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

FATE : 31.68 (-2.31%)
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

FATE : 31.68 (-2.31%)
ALEC : 33.11 (+1.25%)
Tesla, Dave & Buster rise; Chewy, Macquarie fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Friday:

XOM : 46.28 (+1.78%)
LEG : 31.79 (+3.92%)
LULU : 308.69 (+2.86%)
FATE : 31.68 (-2.31%)
CHWY : 45.09 (+1.46%)
TSLA : 898.10 (+7.56%)
JNJ : 147.19 (-1.05%)
MIC : 29.09 (+2.47%)
Fate Therapeutics Surges on Immunotherapy Deal With J&J

Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company....

JNJ : 147.19 (-1.05%)
CELG : 108.24 (+0.10%)
BMY : 60.29 (+0.95%)
FATE : 31.68 (-2.31%)
Thinking about buying stock in Aytu Bioscience, Citigroup, Chewy, Fate Therapeutics, or General Electric?

InvestorsObserver issues critical PriceWatch Alerts for AYTU, C, CHWY, FATE, and GE.

AYTU : 1.5800 (+6.04%)
C : 49.45 (+3.21%)
FATE : 31.68 (-2.31%)
GE : 6.76 (+2.89%)
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies

ê?· Collaboration leverages Company's iPSC product platform and Janssen's proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates ê?·

FATE : 31.68 (-2.31%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.74 , SEDG +8.80 , THC +0.49 , TER +0.14 , LITE +0.99
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar